Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

ABSTRACT: WEHI-164 tumour samples taken after 75% debulking surgery, followed by treatment with poly(I:C) loaded hydrogel.

ORGANISM(S): Mus musculus

PROVIDER: GSE230269 | GEO | 2023/06/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

Project description:Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

| PRJNA958174 | ENA

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (CT26)

Project description:CT26 tumour samples taken by 90% debulking surgery, followed by treatment with poly(I:C) loaded hydrogel.

2023-06-04 | GSE229950 | GEO

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (CT26)

Project description:Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (CT26)

| PRJNA956879 | ENA

RNA-Seq analysis of the WEHI-231-derived stable cell lines WEHI-control and WEHI-miR-148a

Project description:miRNAs regulate the expression of its targets genes by promoting mRNA degradation and translational repression. The goal of this study is to perform RNA-Seq in control or miR-148a-expressing WEHI-231 cell lines for the identification of miR-148a target genes. WEHI-control and WEHI-miR-148a cells were stimulated with anti-IgM (2 ug/ml) for 14 h. Total RNA was extracted, enriched for polyA-containing RNAs and submitted to RNA-Seq.

2016-02-22 | E-GEOD-75809 | biostudies-arrayexpress

RNA-Seq analysis of the WEHI-231-derived stable cell lines WEHI-control and WEHI-miR-148a

2016-02-22 | GSE75809 | GEO

Timecourse of poly(I:C) treated in vivo fibrosarcoma tumors

Project description:WEHI-164 tumors treated with intratumoral injections of poly(I:C), daily for 6 days

2023-06-04 | GSE229021 | GEO

Mesenchymal stem cell-loaded hydrogel improves surgical treatment for chronic cerebral ischemia

Project description:Chronic cerebral ischemia (CCI) results in a prolonged insufficient blood supply to the brain tissue, leading to impaired neuronal function and subsequent impairment of cognitive and motor abilities. Our previous research showed that in mice with bilateral carotid artery stenosis, the collateral neovascularization post Encephalo-myo-synangiosis (EMS) treatment could be facilitated by bone marrow mesenchymal stem cells (MSCs) transplantation. Considering the advantages of biomaterials, we synthesized and modified a gelatin hydrogel for MSCs encapsulation. We then applied this hydrogel on the brain surface during EMS operation in rats with CCI, and evaluated its impact on cognitive performance and collateral circulation.

2024-06-10 | GSE269005 | GEO

Transcriptome analysis of WEHI B lymphoma cells overexpressing individual NFATc1 proteins

Project description:In lymphocytes, NFATc1 is the most prominent NFAT transcription factor which play a crucial role in the fate and activity of peripheral T and B cells. NFATc1 is synthesized in two prominent isoforms, the inducible short isoform NFATc1/aA and the constitutively expressed long isoform NFATc1/C. Several lines of evidence suggested that both isoforms differ markedly in their function. It was speculated that NFATc1/aA supports the proliferation and survival of lymphocytes, whereas NFATc1/C should support apoptosis and anergy induction. To proof this hypothesis we established WEHI 231 B lymphoma cells that stably (over-) express either NFATc1/aA or NFATc1/C. In preliminary experiments we could should that WEHI cells overexpressing NFATc1/aA were protected against apoptosis induction, while cells overexpressing NFATc1/C should a higher apoptosis rate. Transcriptom analysis of WEHI-231 cells overexpressing either NFATc1/aA or NFATc1/C were performed, along with a control group of WEHI-231 cells overexpressing the E.coli enzyme BirA Ligase (which is also present in all target cell lines since for further molecular assays the NFATc1 proteins were expressed as chimeric protein containing C-terminal bio-tags. The experimental results obtained indicate that the both NFATc1 proteins, NFATc1/aA and NFATc1/C, differ tremendously in their transcriptional properties.

2016-07-01 | E-MTAB-4665 | biostudies-arrayexpress

Towards optimized tissue regeneration: A new 3D printable bioink of alginate/cellulose hydrogel loaded with thrombocyte concentrate

Project description:Introduction: Autologous platelet concentrates (APC) are pro-angiogenic and can promote wound healing and tissue repair, also in combination with other biomaterials. However, challenging defect situations remain demanding. 3D bioprinting of an APC based bioink encapsulated in a hydrogel could overcome this limitation with enhanced physio-mechanical interface, growth factor retention/secretion and defect-personalized shape to ultimately enhance regeneration. Methods: This study used extrusion-based bioprinting to create a novel bioink of alginate/cellulose hydrogel loaded with thrombocyte concentrate. Chemico-physical testing exhibited an amorphous structure characterized by high shape fidelity. Cytotoxicity assay and incubation of human osteogenic sarcoma cells (SaOs2) exposed excellent biocompatibility. ELISA analysis confirmed pro-angiogenic growth factor release of the printed constructs, and co-incubation with HUVECS displayed proper cell viability and proliferation. Chorioallantoic membrane (CAM) assay explored the pro-angiogenic potential of the prints in vivo. Detailed proteome and secretome analysis revealed a substantial amount and homologous presence of pro-angiogenic proteins in the 3D construct. Results: This study demonstrated a 3D bioprinting approach to fabricate a novel bioink of alginate/cellulose hydrogel loaded with thrombocyte concentrate with high shape fidelity, biocompatibility, and substantial pro-angiogenic properties. Conclusion: This approach may be suitable for challenging physiological and anatomical defect situations when translated into clinical use.

2024-06-23 | PXD050629 | Pride

Sinorhizobium medicae strain:164

Project description:Sinorhizobium medicae 164 Resequencing

| PRJNA499363 | ENA